INSIGHT - Post Marketing Surveillance (INSIGHT)
In this international non-interventional post-marketing surveillance study we want to evaluate patient characteristics in HCC patients as well as efficacy and safety of Sorafenib (Nexavar®) treatment under daily-life treatment conditions. Specifically investigated are the tumor status, prior and/ or concomitant surgical, radiological and drug treatment and the duration of Sorafenib treatment.
- In- and outpatients with diagnosis of hepatocellular carcinoma (HCC) and decision taken by the investigator to prescribe Nexavar
- Exclusion criteria must be read in conjunction with the local product information
International Study with Nexavar about safety and efficacy in Carcinoma Hepatocellular therapy (HCC)